Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial – CORRIGENDUM

Zeina Beidas; Anya Ragnhildstveit; Adam Blackman; Thomas Anderson; Emily Fewster; Omer A. Syed; Valentyne Sobolenko; Ismail Kaan Kanca; Tatiana Son; Norman Farb; Rotem Petranker

doi:10.1192/bjo.2026.12000

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial – CORRIGENDUM

Published online by Cambridge University Press: 13 May 2026

Zeina Beidas ,

Anya Ragnhildstveit ,

Valentyne Sobolenko ,

Tatiana Son and

Abstract
References

Rights & Permissions

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Information

Type: Corrigendum
Information: BJPsych Open , Volume 12 , Issue 3 , May 2026 , e136

DOI: https://doi.org/10.1192/bjo.2026.12000 [Opens in a new window]
Creative Commons: This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright: © The Author(s), 2026. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

In the original publication of this article, some of the supplementary material was missing by mistake.

This has since been added to the article, and this correction published.

References

Beidas, Z, Ragnhildstveit, A, Blackman, A, et al. Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial. BJPsych Open. 2026;12(2):e65. doi: 10.1192/bjo.2025.10968 CrossRef Google Scholar